From Individualized to Personalized Medicine in Diabetes: An Expert Overview.

Personalized medicine is an individualized and stratified approach to the management of a disease. Personalized medicine can reform the prevention, prediction, and management of diabetes. Use of genetic information in polygenic and monogenic forms of diabetes can help to identify genetic variants and reclassify patients into pathophysiological subgroups. Targeted diagnostic, preventive, and therapeutic interventions can be defined for these groups for effective management of diabetes. Pharmacogenetics combines genotypic and phenotypic factors to develop personalized care in various pathophysiological subgroups of persons with diabetes. Personalized medicine finds wider utility in monogenic (especially Maturity Onset Diabetes of the Young (MODY) and Neonatal Diabetes Mellitus [NDM]) than in polygenic, diabetes. The most frequently mutated genes in MODY include HNF1A and HNF3A. the common genes responsible for NDM include KCNJ11 and ABCC8 (SUR) genes. These genes influence various aspects of glucose metabolism such as β-cell K-ATP channel modulation, production of insulin and development of pancreas. The Madras Diabetes Research Foundation has fostered research in personalized medicine for diabetes based upon genetic information and has developed a national registry for neonatal diabetes and other monogenic form of diabetes.

[1]  V. Mohan,et al.  Precision Diabetes Is Slowly Becoming a Reality , 2019, Medical Principles and Practice.

[2]  V. Mohan,et al.  GCK Gene Screening and Association of GCK Variants With Gestational Diabetes in North Indian Population , 2018, Clinical medicine insights. Endocrinology and diabetes.

[3]  V. Mohan,et al.  Successful transition to sulphonylurea therapy from insulin in a child with permanent neonatal diabetes due to a KCNJ11 gene mutation , 2018 .

[4]  V. Mohan,et al.  Precision diabetes: Where do we stand today? , 2018, The Indian journal of medical research.

[5]  R. Bergenstal.  Continuous glucose monitoring: transforming diabetes management step by step , 2018, The Lancet.

[6]  Leonard D. Goldstein,et al.  Comprehensive genomic analysis identifies pathogenic variants in maturity-onset diabetes of the young (MODY) patients in South India , 2018, BMC Medical Genetics.

[7]  O. Iwuchukwu,et al.  Using Personalized Medicine in the Management of Diabetes Mellitus , 2017, Pharmacotherapy.

[8]  C. Palmer,et al.  Interaction between variants in the CYP2C9 and POR genes and the risk of sulfonylurea‐induced hypoglycaemia: A GoDARTS Study , 2017, Diabetes, obesity & metabolism.

[9]  V. Mohan,et al.  Use of Freestyle Libre ProTM Flash Glucose Monitoring System in Different Clinical Situations at a Diabetes Centre. , 2017, The Journal of the Association of Physicians of India.

[10]  T. Niu,et al.  KCNJ11, ABCC8 and TCF7L2 polymorphisms and the response to sulfonylurea treatment in patients with type 2 diabetes: a bioinformatics assessment , 2017, BMC Medical Genetics.

[11]  A. Hattersley,et al.  Precision diabetes: learning from monogenic diabetes , 2017, Diabetologia.

[12]  N. Thomas,et al.  Comprehensive Maturity Onset Diabetes of the Young (MODY) Gene Screening in Pregnant Women with Diabetes in India , 2017, PloS one.

[13]  D. Beltramo,et al.  Pharmacogenetics and personalized treatment of type 2 diabetes mellitus , 2016, International Journal of Diabetes in Developing Countries.

[14]  S. Vethakkan,et al.  Clinical and genetic predictors of dipeptidyl peptidase-4 inhibitor treatment response in Type 2 diabetes mellitus. , 2016, Pharmacogenomics.

[15]  R. Holt.  Personalized medicine for diabetes: a special issue , 2016, Diabetic medicine : a journal of the British Diabetic Association.

[16]  V. Mohan,et al.  Clinical experience with ambulatory glucose profile for monitoring glucose control in newly diagnosed type 2 diabetes mellitus on early intensive insulin therapy , 2016, Journal of Diabetology.

[17]  A. Bhargava,et al.  Identification of a novel glucokinase mutation in an Indian woman with GCK-MODY. , 2016, The lancet. Diabetes & endocrinology.

[18]  V. Mohan,et al.  Structure–function studies of HNF1A (MODY3) gene mutations in South Indian patients with monogenic diabetes , 2016, Clinical genetics.

[19]  N. Abdullah,et al.  KCNJ11: Genetic Polymorphisms and Risk of Diabetes Mellitus , 2015, Journal of diabetes research.

[20]  A. Ciccodicola,et al.  Pharmacogenomics of Drug Response in Type 2 Diabetes: Toward the Definition of Tailored Therapies? , 2015, PPAR research.

[21]  T. Pollin,et al.  Personalized medicine in diabetes mellitus: current opportunities and future prospects , 2015, Annals of the New York Academy of Sciences.

[22]  N. Thomas,et al.  Maturity onset diabetes of the young in India – a distinctive mutation pattern identified through targeted next‐generation sequencing , 2015, Clinical endocrinology.

[23]  V. Mohan,et al.  Novel ABCC8 (SUR1) Gene Mutations in Asian Indian Children with Congenital Hyperinsulinemic Hypoglycemia , 2014, Annals of human genetics.

[24]  T. Hansen,et al.  The CTRB1/2 Locus Affects Diabetes Susceptibility and Treatment via the Incretin Pathway , 2013, Diabetes.

[25]  S. Semiz,et al.  Pharmacogenetics and personalized treatment of type 2 diabetes , 2013, Biochemia medica.

[26]  N. Thomas,et al.  Molecular diagnosis of maturity onset diabetes of the young in India , 2013, Indian journal of endocrinology and metabolism.

[27]  Zhaoqian Liu,et al.  Pharmacogenetics of Oral Antidiabetic Drugs: Potential Clinical Application , 2012 .

[28]  V. Mohan,et al.  Association of novel variants in the hepatocyte nuclear factor 4A gene with maturity onset diabetes of the young and early onset type 2 diabetes , 2011, Clinical genetics.

[29]  L. Groop,et al.  Heritability and familiality of type 2 diabetes and related quantitative traits in the Botnia Study , 2011, Diabetologia.

[30]  Xilin Yang,et al.  Genetic variants of the protein kinase C-beta 1 gene and development of end-stage renal disease in patients with type 2 diabetes. , 2010, JAMA.

[31]  G. Müller.  Personalized Prognosis and Diagnosis of Type 2 Diabetes – Vision or Fiction? , 2010, Pharmacology.

[32]  S. Rich,et al.  Genetics of type 1A diabetes. , 2009, The New England journal of medicine.

[33]  T. Kobayashi,et al.  Differential association of HLA with three subtypes of type 1 diabetes: fulminant, slowly progressive and acute-onset , 2009, Diabetologia.

[34]  Helen Schuilenburg,et al.  Genome-wide association study and meta-analysis finds over 40 loci affect risk of type 1 diabetes , 2009, Nature Genetics.

[35]  E. Pearson,et al.  Translating TCF7L2: from gene to function , 2009, Diabetologia.

[36]  G. Remuzzi,et al.  Angiotensin converting enzyme insertion/deletion polymorphism and renoprotection in diabetic and nondiabetic nephropathies. , 2008, Clinical journal of the American Society of Nephrology : CJASN.

[37]  D. Klonoff.  Personalized Medicine for Diabetes , 2008, Journal of diabetes science and technology.

[38]  V. Mohan,et al.  The rs12255372(G/T) and rs7903146(C/T) polymorphisms of the TCF7L2 gene are associated with type 2 diabetes mellitus in Asian Indians. , 2007, Metabolism: clinical and experimental.

[39]  S. R. Kulkarni,et al.  Common variants in the TCF7L2 gene are strongly associated with type 2 diabetes mellitus in the Indian population , 2006, Diabetologia.

[40]  L. P. Van den Heuvel,et al.  Autosomal recessive renal glucosuria attributable to a mutation in the sodium glucose cotransporter (SGLT2) , 2002, Human Genetics.

[41]  A. Arbor,et al.  A Difference Between the Inheritance of Classical Juvenile-onset and Maturity-onset Type Diabetes of Young People , 1975, Diabetes.

[42]  V. Mohan,et al.  Glucokinase gene mutations (MODY 2) in Asian Indians. , 2014, Diabetes technology & therapeutics.

[43]  Raymonda Varon,et al.  Successful bone marrow transplantation in a patient with DNA ligase IV deficiency and bone marrow failure , 2007, Orphanet journal of rare diseases.

[44]  J. Beresford.  The young people , 1933 .

[45]  P. Avery,et al.  Pharmacogenomics and Personalized Medicine Dovepress Open Access to Scientific and Medical Research Open Access Full Text Article Pharmacogenomics in Type Ii Diabetes Mellitus Management: Steps toward Personalized Medicine , 2022 .